https://www.nasdaq.com/press-release/otc-markets-group-welcomes-advaxis-inc.-to-otcqx-2021-12-23
https://www.nasdaq.com/press-release/advaxis-announces-acceptance-for-trading-on-the-otcqx-2021-12-22
https://www.nasdaq.com/press-release/advaxis-to-continue-to-explore-additional-options-to-maximize-stockholder-value-2021
https://www.nasdaq.com/press-release/advaxis-issues-letter-to-stockholders-regarding-recent-special-meeting-results-2021
https://www.nasdaq.com/press-release/advaxis-issues-letter-and-second-video-message-to-stockholders-regarding-upcoming
https://www.nasdaq.com/press-release/nasdaq-grants-advaxis-inc.-an-extension-to-december-20-2021-to-complete-merger
https://www.nasdaq.com/press-release/advaxis-inc.-issues-letter-to-stockholders-2021-11-19
https://www.nasdaq.com/press-release/leading-independent-proxy-advisory-firm-glass-lewis-joins-iss-in-recommending-advaxis
https://www.nasdaq.com/press-release/biosight-encourages-advaxis-stockholders-to-vote-for-proposed-merger-2021-11-11
https://www.nasdaq.com/press-release/advaxis-issues-letter-and-video-message-to-stockholders-regarding-upcoming-special
https://www.nasdaq.com/press-release/leading-independent-proxy-advisory-firm-iss-recommends-advaxis-stockholders-vote-for
https://www.nasdaq.com/press-release/advaxis-reports-3rd-quarter-ended-july-31-2021-financial-results-and-provides-a
https://www.nasdaq.com/press-release/nasdaq-grants-advaxis-inc.-an-extension-to-november-22-2021-to-regain-compliance-with
https://www.nasdaq.com/press-release/advaxis-announces-initiation-of-phase-1-clinical-trial-of-adxs-504-for-the-treatment
https://www.nasdaq.com/press-release/advaxis-to-present-at-the-non-small-cell-lung-cancer-drug-development-summit-2021-07
https://www.nasdaq.com/press-release/advaxis-and-biosight-announce-entry-into-definitive-merger-agreement-2021-07-06
https://www.nasdaq.com/press-release/advaxis-reports-second-quarter-ended-april-30-2021-financial-results-and-provides-a
https://www.nasdaq.com/press-release/advaxis-presents-updated-clinical-data-from-ongoing-phase-1-2-trial-of-adxs-503-in
https://www.nasdaq.com/press-release/advaxis-to-present-at-the-american-society-of-clinical-oncology-asco-2021-annual
https://www.nasdaq.com/press-release/update-advaxis-announces-achievement-of-second-milestone-under-adxs-her2-licensing
https://www.nasdaq.com/press-release/advaxis-announces-receipt-of-second-milestone-payment-under-adxs-her2-licensing
https://www.nasdaq.com/press-release/advaxis-inc.-announces-%2420-million-registered-direct-offering-priced-at-the-market
https://www.nasdaq.com/press-release/advaxis-presents-translational-biomarker-data-from-ongoing-adxs-503-phase-1-2-lung
https://www.nasdaq.com/press-release/advaxis-announces-agreement-with-columbia-university-irving-medical-center-to-fund
https://www.nasdaq.com/press-release/advaxis-to-present-corporate-overview-at-the-benzinga-biotech-small-cap-conference
https://www.nasdaq.com/press-release/advaxis-reports-first-quarter-ended-january-31-2021-financial-results-and-provides-a
https://www.nasdaq.com/press-release/advaxis-to-present-at-the-american-association-for-cancer-research-aacr-2021-annual
https://www.nasdaq.com/press-release/advaxis-reports-fiscal-year-2020-financial-results-and-provides-a-business-update
https://www.nasdaq.com/press-release/advaxis-announces-receipt-of-funding-milestone-payment-under-adxs-her2-licensing
https://www.nasdaq.com/press-release/advaxis-announces-listing-transfer-to-nasdaq-capital-market-and-additional-180-day
https://www.nasdaq.com/press-release/advaxis-inc.-announces-closing-of-%249.2-million-public-offering-2020-11-27
https://www.nasdaq.com/press-release/advaxis-inc.-announces-pricing-of-%248-million-public-offering-2020-11-24
https://www.nasdaq.com/press-release/advaxis-inc.-announces-proposed-public-offering-of-common-stock-and-warrants-to
https://www.nasdaq.com/press-release/advaxis-presents-updated-data-from-ongoing-adxs-503-phase-1-2-lung-cancer-trial-at
https://www.nasdaq.com/press-release/advaxis-adxs-503-hot-lung-demonstrates-pronounced-and-sustained-tumor-control-in
https://www.nasdaq.com/press-release/advaxis-to-present-data-from-ongoing-adxs-503-phase-1-2-clinical-trial-at-sitc-2020
https://www.nasdaq.com/press-release/advaxis-inc.-adopts-limited-duration-stockholder-rights-plan-2020-09-29
https://www.nasdaq.com/press-release/advaxis-announces-fda-clearance-of-new-ind-for-adxs-504-for-treatment-of-prostate
https://www.nasdaq.com/press-release/advaxis-reports-third-quarter-ended-july-31-2020-financial-results-and-provides-a
https://www.nasdaq.com/press-release/advaxis-announces-resignation-of-chief-financial-officer-2020-09-04
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/advaxis-to-present-corporate-overview-at-the-ld-micro-500-virtual-conference-2020-08
https://www.nasdaq.com/press-release/ld-micro-announces-preliminary-list-of-presenters-for-the-ld-500-2020-08-05
https://www.nasdaq.com/press-release/advaxis-announces-common-stock-purchase-agreement-for-up-to-%2420-million-with-lincoln
https://www.nasdaq.com/press-release/advaxis-to-be-featured-in-grand-rounds%3a-a-webinar-in-biotech-and-specialty-pharma
https://www.nasdaq.com/press-release/advaxis-reports-second-quarter-ended-april-30-2020-financial-results-and-provides-a
https://www.nasdaq.com/press-release/advaxis-to-host-second-quarter-financial-results-and-business-update-conference-call
https://www.nasdaq.com/press-release/advaxis-announces-updated-positive-clinical-and-biomarker-data-from-ongoing-phase-1-2
https://www.nasdaq.com/press-release/advaxis-reports-first-quarter-ended-january-31-2020-financial-results-and-provides-a
https://www.nasdaq.com/press-release/advaxis-to-present-at-the-2020-ld-micro-virtual-conference-2020-03-03
https://www.nasdaq.com/press-release/advaxis-announces-updated-positive-clinical-data-in-ongoing-phase-1-2-adxs-503-trial
https://www.nasdaq.com/press-release/advaxis-announces-positive-clinical-data-in-ongoing-phase-1-2-adxs-503-trial-in-nsclc
https://www.nasdaq.com/press-release/advaxis-announces-updated-survival-data-in-phase-1-2-adxs-psa-trial-at-the-asco
https://www.nasdaq.com/press-release/advaxis-and-personalis-announce-research-agreement-to-deploy-immunoid-next-platform
https://www.nasdaq.com/press-release/data-on-advaxis-clinical-programs-to-be-presented-at-upcoming-medical-meetings-2020
https://www.nasdaq.com/press-release/advaxis-inc.-announces-pricing-of-%2410.5-million-registered-direct-offering-2020-01-21
https://www.nasdaq.com/press-release/advaxis-announces-fda-clearance-of-ind-for-adxs-504-for-treatment-of-prostate-cancer
https://www.nasdaq.com/press-release/advaxis-reports-fiscal-year-2019-financial-results-and-provides-a-business-update
https://www.nasdaq.com/press-release/advaxis-to-present-at-12th-annual-ld-micro-main-event-investor-conference-2019-12-04
https://www.nasdaq.com/press-release/advaxis-announces-submission-of-ind-application-for-adxs-hot-drug-candidate-for
https://www.nasdaq.com/press-release/advaxis-announces-business-and-pipeline-update-2019-10-24
https://www.nasdaq.com/press-release/advaxis-and-ucla-enter-collaboration-for-glioblastoma-immunotherapy-discovery
https://www.nasdaq.com/press-release/advaxis-announces-updated-prolonged-survival-data-in-phase-1-2-adxs-psa-trial-2019-10
https://www.nasdaq.com/press-release/advaxis-reports-fiscal-third-quarter-2019-financial-results-and-provides-pipeline
